Benzinga | Nov 9, 2021 11:31AM EST

Concert Pharmaceuticals Q3 EPS $(0.78) Beats $(0.81) Estimate, Sales $500.00K Down From $1.50M YoY

Concert Pharmaceuticals (NASDAQ:CNCE) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.81) by 3.7 percent. This is a 30 percent decrease over losses of $(0.60) per share from the same period last year. The company reported $500.00 thousand in sales this quarter. This is a 66.69 percent decrease over sales of $1.50 million the same period last year.